VJHemOnc is committed to improving our service to you

IMW 2019 | MRD as a prognostic tool in amyloidosis

VJHemOnc is committed to improving our service to you

Surbhi Sidana

Surbhi Sidana, MBBS Mayo Clinic, Rochester, MN, discusses preliminary data regarding the role of measurable residual disease (MRD) as a prognostic tool in light-chain amyloidosis, drawing on results from studies at the Mayo clinic. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter